We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+1.08%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$335M
AUM Growth
+$128M
Cap. Flow
+$125M
Cap. Flow %
37.46%
Top 10 Hldgs %
47.51%
Holding
207
New
53
Increased
79
Reduced
42
Closed
32

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$23.4M
2
SHV icon
iShares 0-1 Year Treasury Bond ETF
SHV
+$12M
3
ETP
Energy Transfer Partners L.p.
ETP
+$7.84M
4
WPZ
Williams Partners L.P.
WPZ
+$6.77M
5
EEP
Enbridge Energy Partners
EEP
+$5.66M

Top Sells

Rank Stock Value
1
TLT icon
iShares 20+ Year Treasury Bond ETF
TLT
+$1.69M
2
WMB icon
Williams Companies
WMB
+$1.69M
3
UBT icon
ProShares Ultra 20+ Year Treasury
UBT
+$1.24M
4
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
+$1.02M
5
TSRO
TESARO, Inc.
TSRO
+$989K

Sector Composition

Rank Sector Weight
1 Energy 57.29%
2 Healthcare 12.14%
3 Utilities 3.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
126
BeOne Medicines Ltd
ONC
$33.8B
$265K 0.08%
8,742
+398
+5% +$12.5K
KDNY
127
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$263K 0.08%
4,622
+420
+10% +$25.4K
CLCD
128
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$263K 0.08%
+7,220
New +$255K
INSM icon
129
Insmed
INSM
$23.2B
$262K 0.08%
19,785
-4,751
-19% -$64.8K
MGNX icon
130
MacroGenics
MGNX
$235M
$261K 0.08%
12,774
+3,012
+31% +$75.8K
ACHN
131
DELISTED
Achillion Pharmaceuticals
ACHN
$259K 0.08%
62,792
+35,877
+133% +$191K
ESPR
132
DELISTED
Esperion Therapeutics
ESPR
$258K 0.08%
20,590
+5,050
+32% +$60.1K
KPTI icon
133
Karyopharm Therapeutics
KPTI
$168M
$258K 0.08%
1,830
-211
-10% -$28.5K
GERN icon
134
Geron
GERN
$911M
$257K 0.08%
124,043
+32,192
+35% +$67.9K
RETA
135
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$255K 0.08%
+11,672
New +$295K
FPRX
136
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$255K 0.08%
5,088
-749
-13% -$39.4K
ARRY
137
DELISTED
Array Biopharma Inc
ARRY
$254K 0.08%
28,953
-46,147
-61% -$340K
INO icon
138
Inovio Pharmaceuticals
INO
$79.8M
$253K 0.08%
3,039
+1,034
+52% +$93.5K
RARE icon
139
Ultragenyx Pharmaceutical
RARE
$2.65B
$252K 0.08%
3,591
-459
-11% -$32.6K
OMED
140
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$252K 0.08%
32,651
+12,382
+61% +$114K
LJPC
141
DELISTED
La Jolla Pharmaceutical Company
LJPC
$251K 0.08%
14,329
+38
+0.3% +$728
ITCI
142
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$250K 0.07%
16,572
+10,129
+157% +$143K
SIOX
143
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$250K 0.07%
2,520
+137
+6% +$14.4K
CRBP icon
144
Corbus Pharmaceuticals
CRBP
$170M
$249K 0.07%
+981
New +$225K
IMMU
145
DELISTED
Immunomedics Inc
IMMU
$249K 0.07%
67,841
-13,169
-16% -$39K
IOVA icon
146
Iovance Biotherapeutics
IOVA
$2.23B
$248K 0.07%
35,641
+2,915
+9% +$20.1K
AGEN
147
Agenus
AGEN
$249M
$247K 0.07%
3,055
-165
-5% -$16.2K
NVAX icon
148
Novavax
NVAX
$1.23B
$247K 0.07%
9,808
+7,930
+422% +$231K
MYOK
149
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$245K 0.07%
+18,884
New +$291K
RIGL icon
150
Rigel Pharmaceuticals
RIGL
$680M
$242K 0.07%
+10,163
New +$291K
4 5
6
7 8

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q4 2016 Portfolio in Review

As of Q4 2016, Virtus ETF Advisers held 207 positions worth $335M, up 62% from $207M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Virtus ETF Advisers deployed $125M of net new capital in Q4 2016, opening 53 new positions and adding to 79 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 107,222 shares worth $24M.

By sector, the portfolio is most concentrated in Energy at 57% of assets, down from 64% a quarter earlier, followed by Healthcare and Utilities.

On the sell side, the largest reduction was Williams Companies, an estimated $1.69M trimmed.

  • Virtus ETF Advisers's largest Q4 2016 buy was State Street SPDR S&P 500 ETF Trust: 107,222 shares worth $24M.
  • Virtus ETF Advisers added most to Energy Transfer Partners L.p. in Q4 2016, an estimated $7.84M increase.
  • Virtus ETF Advisers's biggest Q4 2016 reduction was Williams Companies, cutting an estimated $1.69M.
  • Virtus ETF Advisers fully exited iShares 20+ Year Treasury Bond ETF in Q4 2016, selling an estimated $1.69M.
  • Virtus ETF Advisers's ten largest holdings make up 48% of its $335M portfolio in Q4 2016.
  • Virtus ETF Advisers opened 53 new positions and closed 32 in Q4 2016.
  • Virtus ETF Advisers's portfolio value rose 62% quarter-over-quarter to $335M.

Based on Virtus ETF Advisers's 13F filing for Q4 2016, filed 14 Feb 2017.